RxDoctor Payments Data

Laura Dixon

Family · Louisville, KYNPI 1245485085

Payments from drug & device makers

$8,937in general payments, 2019–2025

Across 38 payments — averaging $235.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • Medtronic$3K
  • Boston Scientific$1K
  • Acadia Pharmaceuticals Inc$130
  • MDD US Operations, LLC$117
  • Novo Nordisk$32
  • plus $51 from 3 others

What the payments were for

  • Consulting fees$2,73031%
  • Speaking & faculty fees$1,23814%
  • Travel & lodging$3,33837%
  • Food & beverage$1,58618%
  • Education$451%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,937 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,801
Medicare patients
108
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate48$380,684
GocovriAmantadine Hcl64$160,865
RytaryCarbidopa/Levodopa51$72,803
Carbidopa-LevodopaCarbidopa/Levodopa286$13,352
AmantadineAmantadine Hcl69$3,844
Rasagiline Mesylate12$2,256
Propranolol Hcl ErPropranolol Hcl29$1,080
Tetrabenazine15$1,061
Propranolol Hcl38$1,028
Topiramate59$756
RivastigmineRivastigmine Tartrate16$506
Carbidopa-Levodopa ErCarbidopa/Levodopa11$428
Donepezil Hcl22$383
Pramipexole DihydrochloridePramipexole Di-Hcl11$358
Primidone11$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$22$380,68448 claims
MDD US Operations, LLCGocovri$117$160,86564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →